ASCENTAGE PHARMA GROUP INTERNATIONAL financial statements
Income statement, balance sheet and cash flow statement for the last 1 fiscal years, taken from the XBRL data ASCENTAGE PHARMA GROUP INTERNATIONAL files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
Revenue
134
Cost of revenue
3.98
Gross profit
130
Research and development
130
Selling and marketing
26.9
General and administrative
25.6
Interest expense
8.83
Pre-tax income
-54.1
Income tax
1.43
Net income to minority interests
-0.03
Net income
-55.5
EPS, basic
-0.18
EPS, diluted
-0.18
Balance sheet
FY2024
Cash and equivalents
122
Receivables
11.4
Inventory
0.9
Total current assets
202
Property, plant and equipment
116
Lease right-of-use assets
7.69
Goodwill
3.38
Accounts payable
12.6
Short-term debt
107
Total current liabilities
160
Lease liabilities
2.85
Total liabilities
321
Total debt
229
Paid-in capital
897
Shareholders' equity
36.2
Minority interests
1.37
Total equity
37.6
Total liabilities and equity
359
Cash flow statement
FY2024
Net income
-55.6
Cash from operations
-15.3
Capital expenditures
-3.33
Cash from investing
-49.6
Debt issued
73.4
Debt repaid
-92.2
Stock issued
73.1
Cash from financing
43.1
Exchange rate effect
1.88
Net change in cash
-21.7
Free cash flow
-18.6
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. Valuation uses the share price of $14.86 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
97.0%
Gross profit / revenue.
Pre-tax margin
-40.3%
Pre-tax income / revenue.
Net margin
-41.3%
Net income / revenue.
FCF margin
-13.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-11.4%
Cash from operations / revenue.
Return on equity (ROE)
-153.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
R&D / revenue
96.6%
Research and development expense / revenue.
Capex / revenue
2.5%
Capital expenditures / revenue.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.26x
Current assets / current liabilities.
Quick ratio
0.84x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.77x
(Cash + short-term investments) / current liabilities.
Debt / equity
6.32x
Total debt / shareholders' equity. Not shown when equity is negative.
Net debt
$106.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.18
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.18
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$1.39B
Share price x shares outstanding.
Enterprise value
$1.49B
Market cap + total debt - cash - short-term investments.
P/S
10.3x
Market cap / revenue.
P/B
38.3x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
42.3x
Market cap / tangible book value, when positive.
EV/Sales
11.1x
Enterprise value / revenue.
FCF yield
-1.3%
Free cash flow / market cap.
Earnings yield
-4.0%
Net income / market cap (the inverse of P/E).
What was ASCENTAGE PHARMA GROUP INTERNATIONAL's revenue in fiscal 2024?
ASCENTAGE PHARMA GROUP INTERNATIONAL reported revenue of $134.3M for fiscal 2024.
Was ASCENTAGE PHARMA GROUP INTERNATIONAL profitable in fiscal 2024?
No. It reported a net loss of $55.5M.
How much free cash flow did ASCENTAGE PHARMA GROUP INTERNATIONAL generate in fiscal 2024?
Cash from operations of $15.3M minus capital expenditures of $3.3M left free cash flow of -$18.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.